Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03723356 · ClinicalTrials.gov registry record
Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)
A clinical trial, sponsored by NYU Langone Health.
- Terminated
- Registry status
- 6
- Enrollment target
NCT03723356: Clinical Trial study, sponsored by NYU Langone Health.
NCT03723356 is a clinical trial that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03723356 was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
Multiple sclerosis (MS) is the most common progressive neurologic disorder to occur in adults of working-age. Despite longstanding recognition of cognitive impairment as a symptom of MS, two obstacles in measurement have limited understanding its biological basis, and therefore identifying targeted options for management. First is the absence of a sensitive and precise measure of cognitive impairment. Second is the absence of an index of disease status linked to brain pathophysiology and cognitive performance. This project overcomes both obstacles to link cognitive impairment to MS disease biomarkers. The absence of a sensitive and precise measure of cognitive impairment, along with the absence of an index of disease status linked to brain pathophysiology and cognitive performance, limits the understanding of the biological basis for multiple sclerosis (MS). This project overcomes both obstacles to link cognitive function to MS disease biomarkers, and provides preliminary evaluation of a disease modifying therapy (Tecfidera) for preserving cognitive function.
Primary Outcome
Attention Network Test (ANT) is a cognitive reaction time test administered on the computer, where the subject indicates when they see a target on a screen.
Interventions
- DIAGNOSTIC_TEST fMRI
- DIAGNOSTIC_TEST Siemens Biograph mMR (molecular MR)
- DIAGNOSTIC_TEST Diffusion Spectrum Imaging (DSI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2021-01-09 |
Why NCT03723356 stopped before completion
NCT03723356 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which fMRI is the first listed.
NCT03723356 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03723356 about?
NCT03723356 is a clinical study titled "Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)". Multiple sclerosis (MS) is the most common progressive neurologic disorder to occur in adults of working-age. Despite longstanding recognition of cognitive impairment as a symptom of MS, two obstacles in measurement have limited understanding its biological basis, and therefore identifying targeted ...
What is the current status of trial NCT03723356?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2018-07-01. Estimated completion is 2021-01-09.
What interventions are being tested in trial NCT03723356?
The interventions under investigation include: fMRI (DIAGNOSTIC_TEST), Siemens Biograph mMR (molecular MR) (DIAGNOSTIC_TEST), Diffusion Spectrum Imaging (DSI) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03723356?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI